Now Enrolling
Advancing wet AMD Treatment Starts with You
Find out if you’re a candidate for the SOL study, a clinical trial for wet age-related macular degeneration
Living with advanced age-related macular degeneration (AMD) isn’t easy, whether you help someone with this condition or have it yourself. If someone in your family has been diagnosed with wet AMD, you may know that the condition is often treated with an anti-VEGF medication (a treatment that suppresses the protein that causes blood vessels to grow and leak), such as a drug called aflibercept.1
Keeping up with frequent injections can be stressful, not to mention time consuming. Without treatment, most people with this advanced form of AMD, called neovascular AMD (or wet AMD), will eventually become legally blind.2
The good news is that
clinical research is
ongoing to develop
investigational treatment options
for wet AMD.
This research includes an investigational (not approved for use outside of clinical trials) drug called OTX-TKI. To determine if this drug is safe and effective, it will be studied in the SOL study.3
You may have heard about this study from your doctor and, if so, you may be eligible to participate. Advancing the treatment of wet AMD can start with you.
Are you interested in joining the SOL study?
Learn more about an investigational treatment for wet AMD being evaluated in this clinical trial.
REFERENCES: 1. American Academy of Ophthalmology. Anti-VEGF treatments. Updated July 26, 2023. Accessed June 28, 2024. https://www.aao.org/eye-health/drugs/anti-vegf-treatments. 2. Hobbs SD, Pierce K. Wet Age-Related Macular Degeneration (AMD). StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. 3. Study to evaluate the efficacy and safety of intravitreal OTX-TKI (Ocular Therapeutix) (axitinib implant) in subjects with neovascular age-related macular degeneration. NCT06223958. Updated July 5, 2024. Accessed July 15, 2024. https://clinicaltrials.gov/study/NCT06223958.